Chiglitazar: a novel pan-PPAR agonist

被引：3
|
作者：
DeFronzo, Ralph A. [1 ]
机构：
[1] Univ Texas Hlth, Diabet Div, San Antonio, TX 78229 USA
来源：
SCIENCE BULLETIN | 2021年 / 66卷 / 15期
关键词：
INSULIN SENSITIVITY; GLYCEMIC CONTROL; PIOGLITAZONE;
D O I：
10.1016/j.scib.2021.04.012
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：1497 / 1498
页数：2
相关论文
共 50 条
  • [1] IMPACT OF LANIFIBRANOR, A PAN-PPAR AGONIST, ON THE PULMONARY VASCULAR TONE
    Nagaraj, Chandran
    Sharma, Neha
    Nagy, Bence
    Junien, Jean-Louis
    Broqua, Pierre
    Konstantinova, Irena
    Olschewski, Andrea
    Kwapiszewska, Grazyna
    Olschewski, Horst
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 452 - 452
  • [2] A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
    Francque, Sven M.
    Bedossa, Pierre
    Ratziu, Vlad
    Anstee, Quentin M.
    Bugianesi, Elisabetta
    Sanyal, Arun J.
    Loomba, Rohit
    Harrison, Stephen A.
    Balabanska, Rozalina
    Mateva, Lyudmila
    Lanthier, Nicolas
    Alkhouri, Naim
    Moreno, Christophe
    Schattenberg, Jorn M.
    Stefanova-Petrova, Diana
    Vonghia, Luisa
    Rouzier, Regine
    Guillaume, Maeva
    Hodge, Alexander
    Romero-Gomez, Manuel
    Huot-Marchand, Philippe
    Baudin, Martine
    Richard, Marie-Paule
    Abitbol, Jean-Louis
    Broqua, Pierre
    Junien, Jean-Louis
    Abdelmalek, Manal F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1547 - 1558
  • [3] In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
    He, B. K.
    Ning, Z. Q.
    Li, Z. B.
    Shan, S.
    Pan, D. S.
    Ko, B. C. B.
    Li, P. P.
    Shen, Z. F.
    Dou, G. F.
    Zhang, B. L.
    Lu, X. P.
    Gao, Y.
    [J]. PPAR RESEARCH, 2012, 2012
  • [4] Advances in Studies of Chiglitazar Sodium, a Novel PPAR Pan-Agonist, for the Treatment of Type 2 Diabetes Mellitus
    Zhang, Xin-hui
    Tian, Yun-fei
    Huang, Guang-liang
    Cui, Wen-yan
    Sun, Qian
    He, Wen-juan
    Liu, Xiu-ju
    [J]. CURRENT MEDICAL SCIENCE, 2023, 43 (05) : 890 - 896
  • [5] Advances in Studies of Chiglitazar Sodium, a Novel PPAR Pan-Agonist, for the Treatment of Type 2 Diabetes Mellitus
    Xin-hui Zhang
    Yun-fei Tian
    Guang-liang Huang
    Wen-yan Cui
    Qian Sun
    Wen-juan He
    Xiu-ju Liu
    [J]. Current Medical Science, 2023, 43 : 890 - 896
  • [6] The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control
    Cooreman, Michael P.
    Francque, Sven
    Dzen, Lucile
    Huot-Marchand, Philippe
    Junien, Jean L.
    Broqua, Pierre
    Abdelmalek, Manal F.
    [J]. DIABETES, 2022, 71
  • [7] Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPARα selective
    Bhurruth-Alcor, Yushma
    Rost, Therese H.
    Jorgensen, Michael R.
    Rajender
    Mueller, Melanie
    Skorve, Jon
    Berge, Rolf K.
    Miller, Andrew D.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (03) : 1252 - 1255
  • [8] Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects
    Yi, Ling
    Zhang, Hua
    Zhang, Jin-wen
    You, Xiao-ming
    Ning, Zhi-qiang
    Yu, Jia
    Qian, Li-fang
    Miao, Li-yan
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (07): : 934 - 941
  • [9] The pan-PPAR agonist lanifibranor significantly improves cardiovascular risk biomarkers in patients with NASH
    Francque, Sven
    Cooreman, Michael
    Baudin, Martine
    Huot-Marchand, Philippe
    Dzen, Lucile
    Louis, Junien Jean
    Broqua, Pierre
    Abdelmalek, Manal
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S268 - S268
  • [10] A novel pan-PPAR agonist (BP-2) normalizes metabolic and inflammatory parameters in vitro and in ob/ob mice
    Sanz, Maria-Jesus
    Marques, Patrice
    Villarroel-Vicente, Carlos
    Collado, Aida
    Garcia, Ainhoa
    Vila, Laura
    Piqueras, L. A. U. R. A.
    Cortes, Diego
    Cabedo, Nuria
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 397 - 400
12345